Skip to content

Geron GERN Restricted Cash

Restricted Cash at other companies

Incyte logo
IncyteINCY
$1.84M+10.3%
Immunome logo
ImmunomeIMNM
$210K+110%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$102K-53.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$0-100%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$416K

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's restricted cash?
Geron (GERN) reported restricted cash of $1.88M in Q1 2026.
How has Geron's restricted cash changed year-over-year?
Geron's restricted cash increased by 1.0% year-over-year, from $1.87M to $1.88M.
What is the long-term trend for Geron's restricted cash?
Over 5 years (2020 to 2025), Geron's restricted cash has grown at a 38.9% compound annual growth rate (CAGR), from $363K to $1.88M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.